Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with
underlying mechanisms that have been primarily investigated in mice after intratracheal …

Single-dose intratracheal bleomycin has been instrumental for understanding fibrotic lung
remodeling, but fails to recapitulate several features of idiopathic pulmonary fibrosis (IPF) …

Idiopathic pulmonary fibrosis (IPF) remains a disease with an unknown cause and a poor
prognosis. Among attempts to define disease pathogenesis, animal models of experimental …

Interstitial lung disease (ILD) comprises a large number of chronic lung disease
characterized by varying degrees of inflammation and fibrosis. Mostly they are idiopathic …

Chronic idiopathic pulmonary fibrosis (IPF) is a progressive, fatal, and untreatable disease
with unclear etiology. There are few models of this chronic pathology, and although delivery …

The preclinical model of bleomycin-induced lung fibrosis, used to investigate mechanisms
related to idiopathic pulmonary fibrosis (IPF), has incorrectly predicted efficacy for several …

Idiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown etiology, for which
there is no curative pharmacological therapy. Bleomycin, an anti-neoplastic agent that …

Animal models can provide considerable benefit for investigating the pathogenesis of the
complex process of fibrosis in the lung. Systems include intratracheal administration of …

Background Idiopathic pulmonary fibrosis (IPF) is a severe and progressive respiratory
disease with poor prognosis. Despite the positive outcomes from recent clinical trials, there …

Large multicenter clinical trials have led to two recently approved drugs for patients with
idiopathic pulmonary fibrosis (IPF); yet, both of these therapies only slow disease …